{"product_id":"toi-pestle-analysis","title":"(TOI) The Oncology Institute, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis The Oncology Institute, Inc. PESTLE Analysis helps you assess political, economic, social, technological, legal, and environmental forces shaping the company and its risks\/opportunities. The page shows a real preview\/sample of the report so you can judge depth and style; purchase the full version to get the complete ready-to-use, company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS healthcare policy dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. depends heavily on US healthcare policy because Medicare, Medicaid, and commercial payer rules drive most oncology reimbursement and patient access. In 2026, even small changes in CMS payment rates, prior auth, or site-of-service rules can quickly shift visit volume, margins, and staffing at clinic level. Oncology care is especially exposed because cancer patients are often older and need repeated, high-cost chronic treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and oncology reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare is central to The Oncology Institute, Inc. because it covers about 66 million people, many of them older cancer patients. In 2025, the Medicare Physician Fee Schedule conversion factor fell to $32.3465, so updates for visits, infusion, radiation, and supportive care can shift revenue per encounter. Federal pressure on Part B drug spending also matters, since lower drug margins can hit infusion and dispensing economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState licensing across 67 clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc.'s 67 clinics expose it to 67 state-level licensing and scope-of-practice regimes, so compliance gets harder with every new site. \u003c\/p\u003e\n\u003cp\u003eRules can differ on physician supervision, infusion standards, pharmacy handling, and how oncology services are delivered, which raises legal and operating risk. \u003c\/p\u003e\n\u003cp\u003eAs the U.S. footprint expands, TOI must keep approvals, staffing, and protocols aligned across states or face delays, penalties, and added cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial and research oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTOI’s trial network depends on FDA rules, NIH grant flows, and local IRB approvals; NCI’s FY2025 budget was about $7.2 billion, so policy shifts can change who enrolls and where sites make money. Trials also help recruit patients and support care quality, which matters when oncology research dollars tighten. 2026 payer and federal support levels will still shape site economics and trial speed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH, FDA, and local IRBs set trial pace.\u003c\/li\u003e\n\u003cli\u003eNCI FY2025 budget: about $7.2 billion.\u003c\/li\u003e\n\u003cli\u003eMore support can lift enrollment and margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health and cancer care priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCancer stays a top U.S. public health priority: the American Cancer Society projected about 2.0 million new cases and 611,720 deaths in 2024. That keeps demand high for The Oncology Institute, Inc.'s specialty oncology care, especially where patients need faster diagnosis and coordinated treatment.\u003c\/p\u003e\n\u003cp\u003ePolicy focus on survivorship and palliative care can lift referrals to integrated cancer centers. If payers and regulators favor outpatient, team-based oncology over fragmented care, TOI can gain share and reduce avoidable acute-care use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh case load supports steady demand.\u003c\/li\u003e\n\u003cli\u003eEarlier diagnosis lifts referral flow.\u003c\/li\u003e\n\u003cli\u003eOutpatient care can cut total costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Cuts and State Rules Pressure Oncology Institute Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for The Oncology Institute, Inc. stays tied to Medicare, Medicaid, and state rules that shape pricing, access, and clinic operations. The 2025 Medicare Physician Fee Schedule conversion factor fell to 32.3465, so payment changes can quickly move margins. With 67 clinics across 67 state regimes, licensing and scope rules add compliance drag. Federal trial funding also matters; NCI FY2025 funding was about 7.2 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare CF\u003c\/td\u003e\n\u003ctd\u003e32.3465\u003c\/td\u003e\n\u003ctd\u003eReimbursement pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e67\u003c\/td\u003e\n\u003ctd\u003eState-rule complexity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI FY2025\u003c\/td\u003e\n\u003ctd\u003e7.2 billion\u003c\/td\u003e\n\u003ctd\u003eTrial support risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal forces shape The Oncology Institute, Inc.'s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise PESTLE snapshot that helps teams quickly spot external risks and opportunities for The Oncology Institute, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, verifiable source list linking each major Oncology Institute claim to industry reports, government data, and trusted benchmarks for faster, defensible decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSenior patient mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. serves adult and senior cancer patients, so demand tracks retirement income and Medicare coverage. The U.S. had about 59 million people age 65+ in 2023, and that group is set to reach about 73 million by 2030; roughly 60% of new cancer cases occur after age 65. Still, fixed incomes can strain travel, copays, and treatment adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-cost drug reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-cost oncology drugs squeeze The Oncology Institute, Inc. because infused and oral therapies often cost tens of thousands of dollars per patient each year, while payment timing can lag. Its on-site infusion and dispensing model depends on the spread between acquisition cost and reimbursement, plus tight inventory control and a favorable payer mix. When specialty-drug inflation rises faster than reimbursement, gross margin can compress fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and government payer mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue at The Oncology Institute, Inc. depends on the split between Medicare, Medicaid, and commercial lives. For the same oncology visit, commercial contracts can pay far more than government rates, so payer mix can swing margins fast. In 2026, tougher payer talks matter as insurers keep pushing total cancer spend lower.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOutpatient site-of-care shift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCancer care keeps shifting from hospitals to outpatient clinics, and that favors The Oncology Institute, Inc.'s lower-cost, clinic-based model. Community oncology can cut patient travel time and, when reimbursement stays fair, improve throughput and margins versus higher-cost hospital outpatient settings. In Medicare, site-neutral payment pressure remains a key tailwind for outpatient providers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower care-delivery costs\u003c\/li\u003e\n\u003cli\u003eBetter patient convenience\u003c\/li\u003e\n\u003cli\u003eHigher throughput potential\u003c\/li\u003e\n\u003cli\u003eDepends on reimbursement support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLabor and operating cost inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLabor and operating costs are a key risk for The Oncology Institute, Inc. because a 67-site network needs physicians, nurses, pharmacists, and clinical trial staff, all facing persistent wage pressure. Rent, utilities, and medical supplies add more strain, and oncology care needs both high-touch staffing and costly infrastructure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e67 sites amplify cost inflation\u003c\/li\u003e\n\u003cli\u003eWages hit margins first\u003c\/li\u003e\n\u003cli\u003eRent, utilities, supplies rise too\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Institute: Growing 65+ Cancer Demand, Margin Pressure Ahead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. is exposed to a growing 65+ cancer market, with about 73 million Americans age 65+ expected by 2030 and roughly 60% of new cancer cases after age 65. Payer mix matters because Medicare and Medicaid reimburse less than commercial plans, so margin swings can be sharp. Inflation in drugs, wages, and clinic overhead can pressure earnings, but outpatient care supports lower-cost delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+ U.S. population\u003c\/td\u003e\n\u003ctd\u003e59M in 2023; 73M by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew cancer cases\u003c\/td\u003e\n\u003ctd\u003e~60% after age 65\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork size\u003c\/td\u003e\n\u003ctd\u003e67 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eThe Oncology Institute, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This PESTLE analysis of The Oncology Institute, Inc. covers political, economic, social, technological, legal, and environmental factors with actionable insights and risk implications. No placeholders—download the same finished file after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing US population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTOI is well placed for an older patient base: in the U.S., people aged 65+ are about 18% of the population, and roughly 60% of new cancer diagnoses and 70% of cancer deaths occur in this group. That supports steady demand for TOI’s adult and senior clinics, since older patients often need longer treatment, more scans, and more follow-up care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer survivorship demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCancer survivorship demand is rising: the U.S. had about 18.1 million cancer survivors in 2022 and that is projected to reach 22.2 million by 2030. As more patients need long-term monitoring, symptom control, and palliative support, The Oncology Institute, Inc.'s integrated model fits the shift from acute treatment to ongoing care. Social expectations now favor continuity, quality of life, and patient navigation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for local care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany oncology patients prefer care close to home because long trips add fatigue, cost, and missed work. The Oncology Institute, Inc.’s 67-clinic footprint supports this need by making infusion and physician visits easier to reach for community-based patients. That matters most for frail, elderly, and immunocompromised patients, where convenience can shape treatment adherence and continuity of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust and care coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrust is central in oncology because care is personal, complex, and often long term; the U.S. recorded about 2.0 million new cancer cases in 2024. The Oncology Institute, Inc.'s physician-led model and support services help patients and families get coordinated, empathetic care, which can lower confusion during treatment changes. Clear communication matters most when decisions affect survival, side effects, and quality of life.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAbout 2.0 million U.S. cases in 2024\u003c\/li\u003e\n\u003cli\u003eTrust drives treatment adherence\u003c\/li\u003e\n\u003cli\u003eCare teams need clear updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGrowing need for palliative support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeed for palliative support is rising as oncology patients want better pain control, counseling, and care planning, not treatment alone. WHO says 60 million people need palliative care each year, but only about 14% receive it. The Oncology Institute, Inc. can meet this demand with a broader service mix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigher awareness of symptom relief.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFamily demand for care planning.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports beyond-curative oncology care.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder Patients Drive Cancer Demand—and Reveal a Major Care Gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTOI benefits from an older, higher-need patient base: about 18% of Americans are 65+, and that group drives roughly 60% of new cancer cases and 70% of cancer deaths. Social demand also favors nearby, coordinated care because patients want less travel, clearer updates, and family support.\u003c\/p\u003e\n\u003cp\u003eTrust and communication matter more in oncology than in most specialties, so a physician-led model can improve adherence and follow-up. Palliative care need is also a social gap: WHO says 60 million people need it yearly, but only about 14% receive it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e18% age 65+\u003c\/td\u003e\n\u003ctd\u003eMore cancer demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePalliative gap\u003c\/td\u003e\n\u003ctd\u003e14% coverage\u003c\/td\u003e\n\u003ctd\u003eMore symptom care need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial management systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. depends on clinical trial management systems to track enrollment, manage complex protocols, and protect data integrity across oncology studies. Oncology trial protocols can run 100+ pages, so digital tools help cut manual errors and speed study execution.\u003c\/p\u003e\n\u003cp\u003eStronger research systems also support cleaner audit trails and faster site coordination, which matters when trials handle high-volume patient data. Better infrastructure can help The Oncology Institute, Inc. join more studies and improve access to research revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOn-site infusion and dispensing technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegrated infusion and medication dispensing at The Oncology Institute, Inc. depends on software, inventory tracking, and barcode safety checks to match the right drug, dose, and patient. These systems help track drug use, cut waste, and improve dose accuracy, which matters when high-cost oncology drugs move through tight schedules. In high-volume clinics, workflow speed and error control are not optional; they directly affect throughput, cost, and care quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElectronic health record integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. runs 67 locations, so electronic health record integration is a key advantage for fast, shared access to patient data across sites. Connected records help clinicians make quicker decisions, manage referrals, and keep follow-up on track, which matters in oncology where treatment delays can raise risk. Interoperability also supports smoother coordination and lower admin drag as patient volume grows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRadiation and diagnostic innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTOI’s radiation therapy depends on advanced planning software and precision machines, and in oncology, about 50% of patients need radiation at some point. Better imaging and dose targeting can cut healthy-tissue exposure, which improves outcomes and lowers side effects. Keeping pace with standards means steady capital spend on scanners, planning systems, and treatment delivery gear.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRadiation needs precision equipment.\u003c\/li\u003e\n\u003cli\u003eImaging improves targeting.\u003c\/li\u003e\n\u003cli\u003eCapital spend keeps TOI current.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTelehealth and digital engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTelehealth stays useful at The Oncology Institute, Inc. for follow-ups, symptom checks, and care coordination, cutting travel for patients between visits. In oncology, where treatment plans often need fast adjustments, remote touchpoints can help keep care on track.\u003c\/p\u003e\n\u003cp\u003eDigital engagement also widens access for patients far from clinics or with mobility limits. The U.S. HHS reports telehealth use remains far above pre-2020 levels, and oncology groups keep using it for education, scheduling, and adherence support.\u003c\/p\u003e\n\u003cp\u003eFor The Oncology Institute, Inc., the value is practical: fewer missed visits, quicker triage, and better monitoring of medicines and side effects. These tools can also improve patient retention when in-person care is hard to reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports follow-ups and symptom checks\u003c\/li\u003e\n\u003cli\u003eImproves access for rural patients\u003c\/li\u003e\n\u003cli\u003eAids scheduling and education\u003c\/li\u003e\n\u003cli\u003eHelps monitor adherence and side effects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmart Tech Powers Safer Oncology Care Across 67 Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. relies on EHR links, trial software, and barcode checks to cut errors, speed care, and protect data across 67 locations. Precision tech also supports infusion, radiation planning, and safer dose delivery.\u003c\/p\u003e\n\u003cp\u003eTelehealth and digital coordination help reduce missed visits, support symptom checks, and improve follow-up for oncology patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork scale\u003c\/td\u003e\n\u003ctd\u003e67 locations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial protocols\u003c\/td\u003e\n\u003ctd\u003e100+ pages\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIPAA data privacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTOI handles diagnoses, medications, and trial data across multiple sites, so HIPAA controls are a must. HHS OCR reported 725 large healthcare breaches in 2024, showing how exposed patient data can be. Strong access control, encryption, and audit logs help TOI cut breach and fine risk while protecting oncology research records.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and research compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. must keep every oncology trial aligned with FDA rules, informed consent, and protocol oversight under 21 CFR Part 312 and 45 CFR 46. Even one major deviation can pause enrollment, delay data readout, and trigger liability. Research governance is a core legal control, because the company’s trial work depends on clean documentation, IRB review, and audit-ready compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState medical practice rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. must follow state rules on physician supervision, prescribing, and outpatient infusion, and those rules differ across all 50 states. That makes a multi-market model harder to run because one site may need different staffing, supervision, or pharmacy controls than another. Licensure and credentialing are not one-time tasks; they must be renewed and tracked for each clinician and facility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBilling and fraud scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology billing draws heavy legal scrutiny because high-cost infusions and frequent visits raise audit risk. CMS estimated Medicare fee-for-service improper payments at $31.7 billion in 2023, so claim coding, drug modifiers, and documentation must be exact to avoid repayments. Risk rises when Medicare and commercial plans use different prior-auth and coding rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-cost drugs trigger audits\u003c\/li\u003e\n\u003cli\u003eExact coding cuts repayment risk\u003c\/li\u003e\n\u003cli\u003ePayer rules differ by plan\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmployment and workplace law\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmployment law is a real operating risk for The Oncology Institute, Inc. because U.S. health care and social assistance employed about 18.4 million people in 2024, so wage, hour, anti-discrimination, and safety rules touch a large workforce. Clinic teams need tight control of nurse, physician, and support staff scheduling, pay, and duties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrack overtime and exempt status\u003c\/li\u003e\n\u003cli\u003ePrevent discrimination claims\u003c\/li\u003e\n\u003cli\u003eTrain on workplace safety\u003c\/li\u003e\n\u003cli\u003eAvoid misclassification disputes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe Oncology Institute Faces Rising Legal and Compliance Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. faces heavy legal risk from HIPAA, FDA trial rules, state licensure, and payer audits. HHS OCR reported 725 large healthcare breaches in 2024, and CMS said Medicare fee-for-service improper payments were $31.7 billion in 2023, so weak controls can quickly turn into fines, refunds, or delays. Tight consent, coding, and credentialing are core defenses.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal area\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy\u003c\/td\u003e\n\u003ctd\u003eBreach fines\u003c\/td\u003e\n\u003ctd\u003e725 breaches in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBilling\u003c\/td\u003e\n\u003ctd\u003eRepayments\u003c\/td\u003e\n\u003ctd\u003e$31.7B improper payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinic energy and waste use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc. runs 67 clinic locations, so energy, water, and medical-waste use stay material to cost control. Infusion and treatment sites also produce regulated waste streams, which raise handling and compliance needs. That makes utility bills and disposal contracts part of both operating margin management and sustainability reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHazardous pharmaceutical disposal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology drugs and contaminated materials need strict disposal controls, because chemotherapy waste, sharps, and pharmacy handling can turn into regulated hazardous waste fast. Safe disposal limits soil and water contamination and helps avoid costly compliance lapses; under EPA rules, hazardous waste generators can face daily penalties. It also protects The Oncology Institute, Inc.'s clinic reputation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical supply shortages and freight delays can hit infusion drugs, PPE, and diagnostic materials, so The Oncology Institute, Inc. needs dual sourcing and higher safety stock. In 2025, storms, heat waves, and wildfire smoke across the U.S. kept disrupting road and air transport, which can delay patient visits and deliveries. With a distributed clinic network, backup scheduling, local inventory, and telehealth fallback are key to keep care moving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related patient access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate risk can block access for older cancer patients: in 2024, the U.S. had 27 billion-dollar weather disasters, and heat, floods, and wildfire smoke can raise missed visits and delayed infusions. Community-based The Oncology Institute, Inc. clinics can shorten travel and lower exposure when roads close or air quality turns poor.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e27 U.S. billion-dollar disasters in 2024\u003c\/li\u003e\n\u003cli\u003eHeat, flood, smoke disrupt transport\u003c\/li\u003e\n\u003cli\u003eLocal clinics cut travel burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations in healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare providers face rising ESG pressure, and the sector is linked to about 4.4% of global net emissions. For The Oncology Institute, Inc., waste, energy use, and responsible buying matter because they shape cost, compliance, and trust across its clinic footprint. Environmental performance is now part of reputation, not just operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrack waste, energy, and procurement\u003c\/li\u003e\n\u003cli\u003eCut costs through resource efficiency\u003c\/li\u003e\n\u003cli\u003eSupport stakeholder trust and reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e67 Clinics, Rising Climate Risk, and ESG Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Oncology Institute, Inc.'s 67 clinics make utilities, waste handling, and hazardous drug disposal direct cost and compliance issues. U.S. climate events added pressure: 27 billion-dollar disasters hit in 2024, and heat, smoke, and floods can disrupt visits and deliveries. ESG scrutiny also matters, since healthcare drives about 4.4% of global net emissions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e67 clinics\u003c\/td\u003e\n\u003ctd\u003eHigher utility and waste load\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e27 U.S. disasters (2024)\u003c\/td\u003e\n\u003ctd\u003eMore access and transport risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4.4% global emissions\u003c\/td\u003e\n\u003ctd\u003eESG pressure on healthcare\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235106889993,"sku":"toi-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/toi-pestle-analysis.webp?v=1785733843","url":"https:\/\/dcfanalyst.com\/products\/toi-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}